Lynnai's  Instablog

__

MSLP, MusclePharm Corporation, MSLP.OB

MSLP is one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products.

MSLP’s products are currently available in 1,200 of the top General Nutrition Centers (GNC) in the United States, as well as Vitamin Shop. MSLP’s award-winning products — Assault®, Battle Fuel®, Bullet Proof®, Combat Powder®, Recon® and Shred Matrix®—are also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.

** Musclepharm sponsered Jake Shields won his UFC debut **

UFC star Jake Shields wore MusclePharm apparel at the UFC 121 co-main event, which took place on October 23 from the Honda Center in Anaheim, California.

Musclepharm sponsered Jake Shields won his UFC debut, but struggled to get it, pulling off a split decision over Martin Kampmann. Shields seemed to be completely gassed by the middle of the second round and struggled to do much in the final seven or eight minutes.

But judges had it 30-27 and 29-28 for Shields and 29-28 for Kampmann, apparently qualifying Shields for a shot at the winner of the welterweight title bout at UFC 124 on Dec. 11 between champion Georges St. Pierre and Josh Koscheck. Yahoo! Sports’ Kevin Iole, Dave Doyle and Dave Meltzer all had it 29-28 Kampmann.

Kampmann never let his hands go, and that may have hurt him with the judges.

UFC 121 Matches draw an estimated 850,000 pay per view buys and is watched by an estimated 10 million viewers.

Furthermore, Bodybuilding.com recently selected MSLP as the Supplement Company of the Month.

Bodybuilding.com recognizes leading supplement companies with products and services that are making a positive impact on the industry and their consumers each month.

MusclePharm is currently ranked #14 on Bodybuilding.com's best selling Company list out of 563 companies.

MusclePharm continues to increase its dominate brand presence in the sports nutrition world with over 1,000 customer product reviews and an average rating of 9.2 out 10.0 on Bodybuilding.com.

More about MSLP at www.musclepharm.com.

**********************

  ARNA, Arena Pharmaceuticals, Inc.

ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

ARNA's most advanced drug candidate, lorcaserin, is intended for weight management and has completed a pivotal Phase 3 clinical trial program.

** The US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding ARNAa's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >/= 30) or patients who are overweight (BMI >/= 27) and have at least one weight-related co-morbid condition.

The FDA has completed its review of the NDA and determined that it cannot approve the application in its present form. In the CRL, the FDA outlined the non-clinical and clinical reasons for their decision.

The non-clinical issues identified by the FDA included diagnostic uncertainty in the classification of mammary masses in female rats, unresolved exposure-response relationship for lorcaserin-emergent mammary adenocarcinoma, and unidentified mode of action and unclear safety margin for lorcaserin-emergent brain astrocytoma.

With respect to the clinical reasons, the FDA stated in the CRL that the weight loss efficacy of lorcaserin in overweight and obese individuals without type 2 diabetes is marginal and recommended that Arena submit the final study report of the BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial.

More about ARNA at www.arenapharm.com

********************************************************************

Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).